Brain Corp’s Robotic Fleet Reaches Milestone of 100 Billion Square Feet Covered Autonomously
Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, today announced that its BrainOS®-powered fleet of autonomous mobile robots have officially reached 100 billion square feet of coverage. In doing so, 6.8 million hours have been given back to employees and operations managers, allowing them to focus on customer experience and other high-value tasks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005781/en/
Brain Corp’s Robotic Fleet Reaches Milestone of 100 Billion Square Feet Covered Autonomously (Graphic: Business Wire)
“We are thrilled to celebrate reaching 100 billion square feet of coverage with our fleet which represents the square footage of the entire commercial space in the United States,” said Eugene Izhikevich, CEO and Founder of Brain Corp. “The milestone represents a clear success of deploying autonomous robots at scale and across multiple industries. As a company committed to continuous improvement, it’s been incredibly gratifying to see such major advances in our fleet’s performance, even as it has been scaled and expanded to operate in multiple new dynamic public environments across the world.”
From October 1, 2020, to October 1, 2021, usage of automated robotics increased across a number of industry sectors with several seeing dramatic year-over-year growth. Increases in square feet covered autonomously within sectors include:
- Retail +40%
- Airports +69%
- Malls +113%
- Education +426%
- Hospitals +2,500%
While Brain Corp’s initial robot fleet growth was centered around retail environments, the significant increases in deployments within other sectors including malls, educational facilities, and hospitals, reflects the ability of BrainOS®-powered robots to learn the key dynamics of new environments, a critical factor in the ongoing advancement of its technology.
Creating AI software to power autonomous robots operating in new, varying environments requires advanced software and sensors that ensure high levels of performance and safety, all while prioritizing security and data protection. BrainOS®-powered robots align with all applicable privacy regulations, processing data exclusively for navigation and operational support without any additional data sources which could identify a natural person.
“As we’ve expanded our fleet size, our focus has always been on safely operating in a variety of different environments,” said Sean Felker, Lead Functional Safety Engineer. “Reaching 100 billion square feet of autonomous coverage is validation that this focus is paying off. We have always been committed to helping customers become more efficient in their operations, and it's a testament to our skilled teams that this is being successfully achieved while prioritizing safety and privacy.”
“This is an exceptionally exciting time to be in the field of robotics and automation,” said Nick Whitney, SVP, Sales America. “Across numerous industries, leaders are reinventing how they operate by combining the data-driven sophistication of automated robots with human teams.”
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data to enable the digital transformation of physical workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 16,000 AMRs, representing the largest fleet of its kind in the world. For more information, visit www.braincorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005781/en/
Contact information
Press
Josh Stanbury
press@braincorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom